Item 8.01 Other Events.

On July 27, 2020, scPharmaceuticals Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted the Company's New Drug Application ("NDA") resubmission for its product candidate, FUROSCIX® , a proprietary, subcutaneously delivered furosemide solution outpatient alternative for the treatment of worsening heart failure due to congestion. The FDA set a Prescription Drug User Fee Act target action date of December 30, 2020 for the completion of its review of the NDA. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.





Item 9.01. Exhibits


(d) Exhibits



99.1   Press release issued by the Company on July 27, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses